Abalos Therapeutics
PrivateLast Round
Grant
Mar 18, 2024
Total Funding Raised
$51.31M
Company Overview
Abalos Therapeutics operates in Healthcare & Life Sciences and is based in Dusseldorf. Its latest recorded funding round was a Grant round in March 2024.
Abalos Therapeutics is a biotechnology company developing a novel anti-cancer approach that uses the unique immune stimulation of the arenavirus to provide the full breadth of the immune system's power specifically against cancer cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abalos Therapeutics Comparables
Compare Abalos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TILT Biotherapeutics | 77% | |
| Candel Therapeutics, Inc. | 75% | |
| Replimune Group Inc. | 73% |
For institutional investors. Book with your work email.
Abalos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 18, 2024 | ||||
| Series A Extension | Oct 14, 2021 | ||||
| Series A | Oct 15, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Abalos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boehringer Ingelheim | Series A Extension, Series A |
| NRW.Bank | Series A Extension, Series A |
| Hx Bio Ventures | Series A Extension |
| Boehringer Ingelheim Venture Fund | Series A Extension, Series A |
| Ventura BioMed Investors | Series A Extension |
| Gründerfonds Ruhr | Series A Extension, Series A |
| High-Tech Gründerfonds | Series A Extension, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 4, 2025
Added Ventura BioMed, a biotechnology startup, as a customer.
For institutional investors. Book with your work email.
Abalos Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Abalos Therapeutics's valuation, stock price, and market status.
Is Abalos Therapeutics a public or private company?
Abalos Therapeutics is a private company.
What is the current stock price of Abalos Therapeutics?
Abalos Therapeutics is a private company, so its shares have no public market price. Caplight tracks Abalos Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Abalos Therapeutics worth (valuation)?
Valuation information for Abalos Therapeutics is not publicly available.
Can I buy Abalos Therapeutics stock?
Abalos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Abalos Therapeutics's last funding round?
Abalos Therapeutics's most recent funding round was Grant on March 18, 2024.
Who are the main investors in Abalos Therapeutics?
Key investors in Abalos Therapeutics include Boehringer Ingelheim, Boehringer Ingelheim Venture Fund, Gründerfonds Ruhr, Seventure Partners.
Will Abalos Therapeutics IPO soon?
No public IPO plans have been announced for Abalos Therapeutics.
How can I track Abalos Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Abalos Therapeutics's shares on secondary markets.